Status:
RECRUITING
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
Lead Sponsor:
Lung Cancer Mutation Consortium
Collaborating Sponsors:
Lung Cancer Research Foundation
Conditions:
NSCLC
Eligibility:
All Genders
Brief Summary
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of ...
Eligibility Criteria
Inclusion
- Clinical stage IA2-III lung cancers
- Potentially resectable if lung cancer suspicion confirmed pathologically
- Operable
Exclusion
- No concurrent malignancy
- No prior lung cancer within last 2 years
- Purely ground glass pulmonary opacity
Key Trial Info
Start Date :
June 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 15 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04712877
Start Date
June 15 2022
End Date
June 15 2026
Last Update
July 17 2024
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis
Davis, California, United States, 95616
2
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
3
UCLA
Los Angeles, California, United States, 90095
4
St. Joseph's Hospital Orange
Orange, California, United States, 92868